Associated Press reports: Hal Barron, chief medical officer for Genentech, a division of Swiss owned Roche, claims Actemra “marks a major step forward” in the treatment of the disease. Actemra was first approved in Japan in 2008. It has also been approved in Europe, India, and a handful of other countries.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment